Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

Johnson & Johnson announces Carvykti demonstrated significantly higher rates of MRD negativity compared to standard therapies in CARTITUDE-4 study: San Diego Wednesday, December 1 ...

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...